JP2015509505A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015509505A5 JP2015509505A5 JP2014558898A JP2014558898A JP2015509505A5 JP 2015509505 A5 JP2015509505 A5 JP 2015509505A5 JP 2014558898 A JP2014558898 A JP 2014558898A JP 2014558898 A JP2014558898 A JP 2014558898A JP 2015509505 A5 JP2015509505 A5 JP 2015509505A5
- Authority
- JP
- Japan
- Prior art keywords
- lipid
- particle
- composition
- item
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000002632 lipids Chemical class 0.000 claims description 82
- 239000002245 particle Substances 0.000 claims description 59
- 239000000203 mixture Substances 0.000 claims description 20
- 125000000217 alkyl group Chemical group 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 14
- 229940124597 therapeutic agent Drugs 0.000 claims description 14
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 12
- 241000124008 Mammalia Species 0.000 claims description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 10
- 239000004055 small Interfering RNA Substances 0.000 claims description 10
- -1 dimethylamino, diethylamino Chemical group 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 230000002452 interceptive effect Effects 0.000 claims description 8
- 108020004459 Small interfering RNA Proteins 0.000 claims description 6
- 235000012000 cholesterol Nutrition 0.000 claims description 6
- 150000003904 phospholipids Chemical class 0.000 claims description 6
- 229920006395 saturated elastomer Polymers 0.000 claims description 6
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 4
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 4
- 230000002776 aggregation Effects 0.000 claims description 4
- 238000004220 aggregation Methods 0.000 claims description 4
- 150000001408 amides Chemical class 0.000 claims description 4
- 150000004657 carbamic acid derivatives Chemical class 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 108091070501 miRNA Proteins 0.000 claims description 4
- 239000002679 microRNA Substances 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 150000007523 nucleic acids Chemical group 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 125000003282 alkyl amino group Chemical group 0.000 claims description 2
- 150000001841 cholesterols Chemical class 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 2
- 125000001033 ether group Chemical group 0.000 claims description 2
- 150000002170 ethers Chemical class 0.000 claims description 2
- 230000002209 hydrophobic effect Effects 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000019423 liver disease Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 239000000758 substrate Substances 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 238000000034 method Methods 0.000 description 11
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261602990P | 2012-02-24 | 2012-02-24 | |
| US61/602,990 | 2012-02-24 | ||
| PCT/US2013/027469 WO2013126803A1 (en) | 2012-02-24 | 2013-02-22 | Trialkyl cationic lipids and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017236756A Division JP6789918B2 (ja) | 2012-02-24 | 2017-12-11 | トリアルキルカチオン性脂質およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015509505A JP2015509505A (ja) | 2015-03-30 |
| JP2015509505A5 true JP2015509505A5 (enExample) | 2015-12-10 |
| JP6275655B2 JP6275655B2 (ja) | 2018-02-07 |
Family
ID=47884528
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014558898A Active JP6275655B2 (ja) | 2012-02-24 | 2013-02-22 | トリアルキルカチオン性脂質およびその使用方法 |
| JP2017236756A Active JP6789918B2 (ja) | 2012-02-24 | 2017-12-11 | トリアルキルカチオン性脂質およびその使用方法 |
| JP2020184356A Active JP7110297B2 (ja) | 2012-02-24 | 2020-11-04 | トリアルキルカチオン性脂質およびその使用方法 |
| JP2022115626A Pending JP2022140533A (ja) | 2012-02-24 | 2022-07-20 | トリアルキルカチオン性脂質およびその使用方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017236756A Active JP6789918B2 (ja) | 2012-02-24 | 2017-12-11 | トリアルキルカチオン性脂質およびその使用方法 |
| JP2020184356A Active JP7110297B2 (ja) | 2012-02-24 | 2020-11-04 | トリアルキルカチオン性脂質およびその使用方法 |
| JP2022115626A Pending JP2022140533A (ja) | 2012-02-24 | 2022-07-20 | トリアルキルカチオン性脂質およびその使用方法 |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US9352042B2 (enExample) |
| EP (3) | EP2817287B1 (enExample) |
| JP (4) | JP6275655B2 (enExample) |
| KR (4) | KR102075810B1 (enExample) |
| CN (2) | CN110003030A (enExample) |
| AU (1) | AU2013222179B2 (enExample) |
| BR (1) | BR112014020824B1 (enExample) |
| CA (1) | CA2865412C (enExample) |
| CY (1) | CY1121232T1 (enExample) |
| DK (1) | DK2817287T3 (enExample) |
| ES (2) | ES2702874T3 (enExample) |
| HR (1) | HRP20182156T1 (enExample) |
| HU (1) | HUE041494T2 (enExample) |
| IL (3) | IL234266B (enExample) |
| LT (1) | LT2817287T (enExample) |
| MX (3) | MX392812B (enExample) |
| NZ (1) | NZ700075A (enExample) |
| PH (1) | PH12014501901B1 (enExample) |
| PL (1) | PL2817287T3 (enExample) |
| PT (1) | PT2817287T (enExample) |
| RS (1) | RS58077B1 (enExample) |
| RU (2) | RU2718053C2 (enExample) |
| SG (1) | SG11201405157PA (enExample) |
| SI (1) | SI2817287T1 (enExample) |
| UA (1) | UA120026C2 (enExample) |
| WO (1) | WO2013126803A1 (enExample) |
| ZA (1) | ZA201406896B (enExample) |
Families Citing this family (239)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME03091B (me) | 2009-12-01 | 2019-01-20 | Translate Bio Inc | Isporuka irnk za povećanje ekspresije proteina i enzima u humanim genetskim oboljenjima |
| US8853377B2 (en) | 2010-11-30 | 2014-10-07 | Shire Human Genetic Therapies, Inc. | mRNA for use in treatment of human genetic diseases |
| PT2717893T (pt) | 2011-06-08 | 2019-08-20 | Translate Bio Inc | Composições de nanopartículas lipídicas e métodos para transferência de arnm |
| EP3998064A1 (en) | 2011-06-08 | 2022-05-18 | Translate Bio, Inc. | Cleavable lipids |
| NZ700075A (en) | 2012-02-24 | 2016-05-27 | Protiva Biotherapeutics Inc | Trialkyl cationic lipids and methods of use thereof |
| HK1206645A1 (en) | 2012-03-29 | 2016-01-15 | Shire Human Genetic Therapies, Inc. | Ionizable cationic lipids |
| CN104487055A (zh) | 2012-03-29 | 2015-04-01 | 夏尔人类遗传性治疗公司 | 脂质衍生的中性纳米颗粒 |
| BR112014030677A2 (pt) | 2012-06-08 | 2022-07-19 | Shire Human Genetic Therapies | distribuição pulmonar de mrna para células-alvo não-pulmonares |
| US20150267192A1 (en) | 2012-06-08 | 2015-09-24 | Shire Human Genetic Therapies, Inc. | Nuclease resistant polynucleotides and uses thereof |
| US10258698B2 (en) | 2013-03-14 | 2019-04-16 | Modernatx, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| HUE055044T2 (hu) | 2013-03-14 | 2021-10-28 | Translate Bio Inc | MRNS-kódolt ellenanyagok bejuttatására szolgáló eljárások és készítmények |
| KR20150128687A (ko) | 2013-03-14 | 2015-11-18 | 샤이어 휴먼 지네틱 테라피즈 인크. | 메신저 rna의 정제 방법 |
| CA2904151C (en) | 2013-03-14 | 2023-09-12 | Shire Human Genetic Therapies, Inc. | Cftr mrna compositions and related methods and uses |
| ES3032013T3 (en) | 2013-03-15 | 2025-07-14 | Translate Bio Inc | Synergistic enhancement of the delivery of nucleic acids via blended formulations |
| WO2015011633A1 (en) | 2013-07-23 | 2015-01-29 | Protiva Biotherapeutics, Inc. | Compositions and methods for delivering messenger rna |
| EP3041938A1 (en) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| EA201992208A1 (ru) | 2013-10-22 | 2020-07-31 | Транслейт Био, Инк. | ЛЕЧЕНИЕ ФЕНИЛКЕТОНУРИИ С ПРИМЕНЕНИЕМ мРНК |
| WO2015061467A1 (en) | 2013-10-22 | 2015-04-30 | Shire Human Genetic Therapies, Inc. | Lipid formulations for delivery of messenger rna |
| BR112016009014B1 (pt) | 2013-10-22 | 2024-02-06 | Translate Bio, Inc | USO DE COMPOSIÇÃO COMPREENDENDO mRNA PARA DEFICIÊNCIA DE ARGININOSSUCINATO SINTETASE |
| CN105658800A (zh) | 2013-10-22 | 2016-06-08 | 夏尔人类遗传性治疗公司 | Mrna的cns递送及其用途 |
| KR102739894B1 (ko) | 2014-04-25 | 2024-12-05 | 샤이어 휴먼 지네틱 테라피즈 인크. | 메신저 rna 의 정제 방법 |
| US10022455B2 (en) | 2014-05-30 | 2018-07-17 | Translate Bio, Inc. | Biodegradable lipids for delivery of nucleic acids |
| AU2015279968B2 (en) | 2014-06-24 | 2019-11-14 | Translate Bio, Inc. | Stereochemically enriched compositions for delivery of nucleic acids |
| IL289934B2 (en) | 2014-06-25 | 2023-04-01 | Acuitas Therapeutics Inc | Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| CN106456547B (zh) | 2014-07-02 | 2021-11-12 | 川斯勒佰尔公司 | 信使rna的包封 |
| EP3169693B1 (en) | 2014-07-16 | 2022-03-09 | ModernaTX, Inc. | Chimeric polynucleotides |
| EP3171895A1 (en) | 2014-07-23 | 2017-05-31 | Modernatx, Inc. | Modified polynucleotides for the production of intrabodies |
| ES2799409T3 (es) * | 2014-08-07 | 2020-12-17 | Takeda Pharmaceuticals Co | Lípido catiónico |
| US9339029B2 (en) | 2014-09-04 | 2016-05-17 | Preceres Inc. | Hydrazinyl lipidoids and uses thereof |
| WO2016090262A1 (en) | 2014-12-05 | 2016-06-09 | Shire Human Genetic Therapies, Inc. | Messenger rna therapy for treatment of articular disease |
| JP2018509406A (ja) * | 2015-03-11 | 2018-04-05 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | フィロウイルス感染症の処置のための方法及び医薬組成物 |
| US10172924B2 (en) | 2015-03-19 | 2019-01-08 | Translate Bio, Inc. | MRNA therapy for pompe disease |
| EP3289083A4 (en) | 2015-04-27 | 2018-12-19 | The Trustees Of The University Of Pennsylvania | Nucleoside-modified rna for inducing an adaptive immune response |
| CN114085198A (zh) * | 2015-06-29 | 2022-02-25 | 爱康泰生治疗公司 | 用于递送核酸的脂质和脂质纳米颗粒制剂 |
| EP3350157B1 (en) | 2015-09-17 | 2022-01-05 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| ES2862412T3 (es) | 2015-10-14 | 2021-10-07 | Translate Bio Inc | Modificación de enzimas relacionados con el ARN para producción mejorada |
| CA3002922A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| RS63986B1 (sr) | 2015-10-28 | 2023-03-31 | Acuitas Therapeutics Inc | Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina |
| SI3394030T1 (sl) | 2015-12-22 | 2022-04-29 | Modernatx, Inc. | Sestave za doziranje sredstev v celice |
| LT3394093T (lt) | 2015-12-23 | 2022-04-25 | Modernatx, Inc. | Ox40 ligandus koduojančių polinukleotidų naudojimo būdai |
| EP3400023A1 (en) | 2016-01-10 | 2018-11-14 | ModernaTX, Inc. | Therapeutic mrnas encoding anti ctla-4 antibodies |
| CN109072223B (zh) | 2016-04-08 | 2022-10-21 | 川斯勒佰尔公司 | 多聚体编码核酸及其用途 |
| MA45052A (fr) | 2016-05-18 | 2019-03-27 | Modernatx Inc | Polynucléotides codant pour jagged1 pour le traitement du syndrome d'alagille |
| EP3469074B1 (en) | 2016-06-13 | 2020-12-09 | Translate Bio, Inc. | Messenger rna therapy for the treatment of ornithine transcarbamylase deficiency |
| AU2017286980B2 (en) | 2016-06-30 | 2023-10-26 | Arbutus Biopharma Corporation | Compositions and methods for delivering messenger RNA |
| US12491261B2 (en) | 2016-10-26 | 2025-12-09 | Acuitas Therapeutics, Inc. | Lipid nanoparticle formulations |
| US11583504B2 (en) | 2016-11-08 | 2023-02-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| US11241490B2 (en) | 2017-01-11 | 2022-02-08 | The Trustees Of The University Of Pennsylvania | Nucleoside-modified RNA for inducing an immune response against zika virus |
| MX2019010155A (es) | 2017-02-27 | 2020-12-10 | Translate Bio Inc | Arnm de cftr optimizado por codón novedoso. |
| ES2911186T3 (es) | 2017-03-15 | 2022-05-18 | Modernatx Inc | Formas cristalinas de aminolípidos |
| US11752206B2 (en) | 2017-03-15 | 2023-09-12 | Modernatx, Inc. | Herpes simplex virus vaccine |
| FI3596041T3 (fi) | 2017-03-15 | 2023-01-31 | Yhdiste ja koostumuksia terapeuttisten aineiden antamiseen solun sisään | |
| JP7332478B2 (ja) | 2017-03-15 | 2023-08-23 | モデルナティエックス インコーポレイテッド | 脂質ナノ粒子製剤 |
| KR102842382B1 (ko) | 2017-03-24 | 2025-08-04 | 큐어백 에스이 | Crispr-연관 단백질을 암호화하는 핵산 및 이의 용도 |
| WO2018191657A1 (en) | 2017-04-13 | 2018-10-18 | Acuitas Therapeutics, Inc. | Lipids for delivery of active agents |
| WO2018200943A1 (en) | 2017-04-28 | 2018-11-01 | Acuitas Therapeutics, Inc. | Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| FR3066115B1 (fr) * | 2017-05-10 | 2019-06-28 | Universite de Bordeaux | Comprimes de vecteurs d'acides nucleiques |
| WO2018213476A1 (en) | 2017-05-16 | 2018-11-22 | Translate Bio, Inc. | Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr |
| US11421011B2 (en) | 2017-05-18 | 2022-08-23 | Modernatx, Inc. | Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof |
| EP3638292A1 (en) | 2017-06-14 | 2020-04-22 | ModernaTX, Inc. | Polynucleotides encoding coagulation factor viii |
| EP3638678B1 (en) | 2017-06-14 | 2025-12-03 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of agents |
| US11786607B2 (en) | 2017-06-15 | 2023-10-17 | Modernatx, Inc. | RNA formulations |
| US20210228738A1 (en) | 2017-07-17 | 2021-07-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins |
| WO2019036008A1 (en) | 2017-08-16 | 2019-02-21 | Acuitas Therapeutics, Inc. | LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS |
| JP7461872B2 (ja) | 2017-08-17 | 2024-04-04 | アクイタス セラピューティクス インコーポレイテッド | 脂質ナノ粒子製剤における使用のための脂質 |
| WO2019036028A1 (en) | 2017-08-17 | 2019-02-21 | Acuitas Therapeutics, Inc. | LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS |
| WO2019036030A1 (en) | 2017-08-17 | 2019-02-21 | Acuitas Therapeutics, Inc. | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS |
| MA49914A (fr) | 2017-08-18 | 2021-04-21 | Modernatx Inc | Procédés analytiques par hplc |
| AU2018326799A1 (en) | 2017-08-31 | 2020-02-27 | Modernatx, Inc. | Methods of making lipid nanoparticles |
| WO2019126593A1 (en) | 2017-12-20 | 2019-06-27 | Translate Bio, Inc. | Improved composition and methods for treatment of ornithine transcarbamylase deficiency |
| CN118512596A (zh) * | 2017-12-27 | 2024-08-20 | 武田药品工业株式会社 | 含核酸脂质纳米粒子及其用途 |
| SG11202101356YA (en) | 2018-08-10 | 2021-03-30 | Takeda Pharmaceuticals Co | Cationic lipid |
| US12545931B2 (en) | 2018-08-10 | 2026-02-10 | Takeda Pharmaceutical Company Limited | Method for transfection into cardiomyocytes using cationic lipid |
| WO2020041793A1 (en) | 2018-08-24 | 2020-02-27 | Translate Bio, Inc. | Methods for purification of messenger rna |
| WO2020061284A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Peg lipids and uses thereof |
| EP4509118A3 (en) | 2018-09-19 | 2025-05-14 | ModernaTX, Inc. | High-purity peg lipids and uses thereof |
| EP3853202A1 (en) | 2018-09-19 | 2021-07-28 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| US12090235B2 (en) | 2018-09-20 | 2024-09-17 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| EP4613367A1 (en) | 2018-09-21 | 2025-09-10 | Acuitas Therapeutics, Inc. | Systems and methods for manufacturing lipid nanoparticles and liposomes |
| JP7555123B2 (ja) | 2018-10-09 | 2024-09-24 | ザ ユニヴァーシティ オブ ブリティッシュ コロンビア | 有機溶媒不含かつ劣化剤不含のトランスフェクション・コンピテント・ベシクルを含む組成物及びシステム並びにそれらに関連する方法 |
| CN112912509B (zh) | 2018-10-18 | 2024-12-31 | 武田药品工业株式会社 | T细胞的活化/增殖方法 |
| EA202191313A1 (ru) * | 2018-11-09 | 2022-01-26 | Арбутус Биофарма Корпорэйшн | Композиции на основе липидных наночастиц |
| EP3877522A4 (en) * | 2018-11-09 | 2022-11-02 | Arbutus Biopharma Corporation | LIPID DNA NOPARTICLE FORMULATIONS |
| MX2021005969A (es) | 2018-11-21 | 2021-09-14 | Translate Bio Inc | Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr nebulizado. |
| US12070495B2 (en) | 2019-03-15 | 2024-08-27 | Modernatx, Inc. | HIV RNA vaccines |
| US20220305117A1 (en) | 2019-06-18 | 2022-09-29 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and hbv-targeting rnai |
| EP3986915A1 (en) | 2019-06-18 | 2022-04-27 | Janssen Sciences Ireland Unlimited Company | Recombinant interleukin 12 construct and uses thereof |
| CA3143634A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 antibody |
| EP3986454A1 (en) | 2019-06-18 | 2022-04-27 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 or anti-pd-l1 antibody |
| WO2020255010A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of recombinant interleukin 12 construct and hepatitis b virus (hbv) vaccines |
| EP3986563A1 (en) | 2019-06-20 | 2022-04-27 | Janssen Sciences Ireland Unlimited Company | Lipid nanoparticle or liposome delivery of hepatitis b virus (hbv) vaccines |
| KR102928289B1 (ko) * | 2019-06-29 | 2026-02-20 | 글로벌 라이프 사이언시즈 솔루션즈 캐나다 유엘씨 | 핵산 전달을 위한 이온화 가능한 지질 |
| CN114423869A (zh) | 2019-07-19 | 2022-04-29 | 旗舰先锋创新Vi有限责任公司 | 重组酶组合物和使用方法 |
| KR20220103923A (ko) * | 2019-09-19 | 2022-07-25 | 모더나티엑스, 인크. | 치료제의 세포내 전달을 위한 신규한 헤드기 지질 화합물 및 조성물 |
| BR112022004759A2 (pt) | 2019-09-19 | 2022-06-21 | Modernatx Inc | Composições e compostos lipídicos com cauda ramificada para entrega intracelular de agentes terapêuticos |
| EP4048807A1 (en) | 2019-09-23 | 2022-08-31 | Omega Therapeutics, Inc. | Compositions and methods for modulating apolipoprotein b (apob) gene expression |
| CA3147643A1 (en) | 2019-09-23 | 2021-04-01 | Omega Therapeutics, Inc. | Compositions and methods for modulating hepatocyte nuclear factor 4-alpha (hnf4.alpha.) gene expression |
| KR20240130161A (ko) * | 2019-10-22 | 2024-08-29 | 제네반트 사이언시즈 게엠베하 | 오르니틴 트랜스카르바밀라제 (otc) 구축물 및 그의 사용 방법 |
| EP4118207A1 (en) | 2020-03-11 | 2023-01-18 | Omega Therapeutics, Inc. | Compositions and methods for modulating forkhead box p3 (foxp3) gene expression |
| US20230150926A1 (en) * | 2020-03-17 | 2023-05-18 | Genevant Sciences Gmbh | Cationic lipids for lipid nanoparticle delivery of therapeutics to hepatic stellate cells |
| IL296660A (en) | 2020-03-24 | 2022-11-01 | Generation Bio Co | Non-viral dna vectors and uses thereof for expressing factor ix therapeutics |
| CA3172591A1 (en) | 2020-03-24 | 2021-09-30 | Douglas Anthony KERR | Non-viral dna vectors and uses thereof for expressing gaucher therapeutics |
| EP4153223A1 (en) | 2020-05-20 | 2023-03-29 | Flagship Pioneering Innovations VI, LLC | Immunogenic compositions and uses thereof |
| JP2023526422A (ja) | 2020-05-20 | 2023-06-21 | フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー | コロナウイルス抗原組成物及びそれらの使用 |
| AU2021281453A1 (en) | 2020-05-29 | 2022-11-17 | Flagship Pioneering Innovations Vi, Llc. | Trem compositions and methods relating thereto |
| CN116018405A (zh) | 2020-05-29 | 2023-04-25 | 旗舰先锋创新Vi有限责任公司 | Trem组合物及其相关方法 |
| IL299571A (en) | 2020-07-08 | 2023-02-01 | Janssen Sciences Ireland Unlimited Co | Rna replicon vaccines against hbv |
| DK4182297T3 (da) | 2020-07-16 | 2025-12-01 | Acuitas Therapeutics Inc | Kationiske lipider til brug i lipid-nanopartikler |
| EP4189098A1 (en) | 2020-07-27 | 2023-06-07 | Anjarium Biosciences AG | Compositions of dna molecules, methods of making therefor, and methods of use thereof |
| IL300111A (en) | 2020-08-06 | 2023-03-01 | Modernatx Inc | The vehicles for the transfer of cargo molecules to the airway epithelium |
| MX2023002439A (es) | 2020-09-03 | 2023-05-09 | Flagship Pioneering Innovations Vi Llc | Composiciones immunogénicas y usos de las mismas. |
| CZ310613B6 (cs) | 2020-09-23 | 2026-01-28 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Lipidoidy pro transfekci nukleových kyselin a jejich použití |
| JP2023545420A (ja) * | 2020-10-12 | 2023-10-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 高分子を細胞に送達するためのエンドソームエスケープドメイン |
| EP4229208A4 (en) | 2020-10-14 | 2024-10-30 | George Mason Research Foundation, Inc. | METHOD FOR THE PRODUCTION OF LIPID DNANOPARTICLES AND COMPOSITIONS THEREOF |
| KR20230122081A (ko) | 2020-12-18 | 2023-08-22 | 제네반트 사이언시즈 게엠베하 | Peg 지질 및 지질 나노입자 |
| WO2022133230A1 (en) | 2020-12-18 | 2022-06-23 | Janssen Pharmaceuticals, Inc. | Combination therapy for treating hepatitis b virus infection |
| KR20230135585A (ko) | 2020-12-23 | 2023-09-25 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | 변형된 trem의 조성물 및 이의 용도 |
| JP2024501022A (ja) | 2020-12-28 | 2024-01-10 | アークトゥルス セラピューティクス， インコーポレイテッド | Ｈｂｖを標的とする転写活性化因子様エフェクターヌクレアーゼ（ｔａｌｅｎ） |
| CN116887812A (zh) | 2021-02-26 | 2023-10-13 | 埃泽瑞斯公司 | 用于气溶胶形成的制剂以及用于递送核酸的气溶胶 |
| US11952461B2 (en) | 2021-03-22 | 2024-04-09 | Sunbio, Inc. | Siloxy polyethylene glycol and derivatives thereof |
| CA3214085A1 (en) | 2021-03-31 | 2022-10-06 | Darby Rye Schmidt | Thanotransmission polypeptides and their use in treating cancer |
| CN115197079A (zh) * | 2021-04-08 | 2022-10-18 | 厦门赛诺邦格生物科技股份有限公司 | 一种聚乙二醇化脂质及其修饰的脂质体、含该脂质体的药物组合物及其制剂和应用 |
| AU2022260111A1 (en) | 2021-04-20 | 2023-11-30 | Anjarium Biosciences Ag | Compositions of dna molecules encoding amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase, methods of making thereof, and methods of use thereof |
| EP4329884A1 (en) | 2021-04-27 | 2024-03-06 | Generation Bio Co. | Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof |
| AU2022264509A1 (en) | 2021-04-27 | 2023-12-14 | Generation Bio Co. | Non-viral dna vectors expressing therapeutic antibodies and uses thereof |
| WO2022229903A1 (en) | 2021-04-28 | 2022-11-03 | Genevant Sciences Gmbh | Mrna delivery constructs and methods of using the same |
| CN112979483B (zh) * | 2021-05-14 | 2021-08-06 | 苏州艾博生物科技有限公司 | 一种阳离子脂质化合物、包含其的组合物及应用 |
| WO2023283359A2 (en) | 2021-07-07 | 2023-01-12 | Omega Therapeutics, Inc. | Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression |
| JP2024528697A (ja) | 2021-07-20 | 2024-07-30 | エイジーエス・セラピューティクス・ソシエテ・パール・アクシオン・サンプリフィエ | 微細藻類由来の細胞外小胞、その調製および使用 |
| EP4377457A1 (en) | 2021-07-26 | 2024-06-05 | Flagship Pioneering Innovations VI, LLC | Trem compositions and uses thereof |
| AR127073A1 (es) | 2021-09-17 | 2023-12-13 | Flagship Pioneering Innovations Vi Llc | Composiciones y métodos para producir polirribonucleótidos circulares |
| AU2022370530A1 (en) | 2021-10-18 | 2024-05-02 | Flagship Pioneering Innovations Vi, Llc | Compositions and methods for purifying polyribonucleotides |
| TW202334080A (zh) | 2021-11-08 | 2023-09-01 | 美商歐納醫療公司 | 用於遞送環狀聚核苷酸之脂質奈米粒子組合物 |
| JP2024545584A (ja) | 2021-11-12 | 2024-12-10 | モデルナティエックス インコーポレイテッド | ペイロード分子を気道上皮に送達するための組成物 |
| JP2024541467A (ja) | 2021-11-24 | 2024-11-08 | フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー | コロナウイルス免疫原組成物及びそれらの使用 |
| IL312965A (en) | 2021-11-24 | 2024-07-01 | Flagship Pioneering Innovations Vi Llc | Immunogenic compositions and their uses |
| JP2024541466A (ja) | 2021-11-24 | 2024-11-08 | フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー | 水痘帯状疱疹ウイルス免疫原組成物及びその使用 |
| WO2023114943A2 (en) | 2021-12-16 | 2023-06-22 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| AU2022413687A1 (en) | 2021-12-17 | 2024-06-27 | Flagship Pioneering Innovations Vi, Llc | Methods for enrichment of circular rna under denaturing conditions |
| EP4453201A1 (en) | 2021-12-22 | 2024-10-30 | Flagship Pioneering Innovations VI, LLC | Compositions and methods for purifying polyribonucleotides |
| JP2025500358A (ja) | 2021-12-23 | 2025-01-09 | フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー | 抗膜融合ポリペプチドをコードする環状ポリリボヌクレオチド |
| CN114957027B (zh) * | 2022-01-13 | 2023-05-19 | 北京悦康科创医药科技股份有限公司 | 一种阳离子脂质化合物、包含其的组合物及用途 |
| WO2023135273A2 (en) | 2022-01-14 | 2023-07-20 | Anjarium Biosciences Ag | Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof |
| WO2023144127A1 (en) | 2022-01-31 | 2023-08-03 | Ags Therapeutics Sas | Extracellular vesicles from microalgae, their biodistribution upon administration, and uses |
| TW202345863A (zh) | 2022-02-09 | 2023-12-01 | 美商現代公司 | 黏膜投與方法及調配物 |
| EP4482962A1 (en) | 2022-02-24 | 2025-01-01 | IO Biotech ApS | Nucleotide delivery of cancer therapy |
| US20250250227A1 (en) * | 2022-02-28 | 2025-08-07 | Shenzhen Shenxin Biotechnology Co., Ltd. | Amino lipid compound, preparation method therefor, composition thereof and use thereof |
| CN119072330A (zh) | 2022-03-14 | 2024-12-03 | 世代生物公司 | 异源初免加强疫苗组合物和使用方法 |
| CN114380724B (zh) * | 2022-03-23 | 2022-05-24 | 深圳市瑞吉生物科技有限公司 | 用于递送核酸的阳离子脂质化合物和组合物及用途 |
| US20250205167A1 (en) | 2022-03-25 | 2025-06-26 | Sail Biomedicines, Inc. | Novel ionizable lipids and lipid nanoparticles and methods of using the same |
| JP2025511756A (ja) | 2022-04-08 | 2025-04-16 | フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー | ワクチン及び関連する方法 |
| CN114685784B (zh) * | 2022-04-26 | 2023-09-15 | 北京清科胜因生物科技有限公司 | 一种用于核酸递送的聚(2-噁唑啉)脂质与脂质纳米颗粒及应用 |
| CN115626983A (zh) * | 2022-04-27 | 2023-01-20 | 北京清科胜因生物科技有限公司 | 一种聚(2-噁唑啉)脂质及脂质纳米颗粒 |
| CA3257006A1 (en) | 2022-05-09 | 2023-11-16 | Flagship Pioneering Innovations Vi, Llc | TREM COMPOSITIONS AND METHODS OF USE FOR TREATING PROLIFERATIVE DISORDERS |
| CN119487196A (zh) | 2022-05-13 | 2025-02-18 | 旗舰创业创新七公司 | 双链dna组合物及相关方法 |
| WO2023218420A1 (en) | 2022-05-13 | 2023-11-16 | Janssen Pharmaceuticals, Inc. | Mrna compositions for inducing latent hiv-1 reversal |
| WO2023233290A1 (en) | 2022-05-31 | 2023-12-07 | Janssen Sciences Ireland Unlimited Company | Rnai agents targeting pd-l1 |
| CN114940756B (zh) * | 2022-06-02 | 2023-11-07 | 北京清科胜因生物科技有限公司 | 一种聚（2-噁唑啉）脂质与脂质纳米颗粒及应用 |
| WO2023232976A1 (en) | 2022-06-03 | 2023-12-07 | Ags Therapeutics Sas | Extracellular vesicles from genetically-modified microalgae containing endogenously-loaded cargo, their preparation, and uses |
| AU2023283348A1 (en) | 2022-06-07 | 2025-01-09 | Generation Bio Co. | Lipid nanoparticle compositions and uses thereof |
| CN117263818A (zh) * | 2022-06-14 | 2023-12-22 | 杭州高田生物医药有限公司 | 阳离子脂质化合物及其制备方法和应用 |
| EP4544043A1 (en) | 2022-06-22 | 2025-04-30 | Flagship Pioneering Innovations VI, LLC | Compositions of modified trems and uses thereof |
| CA3261283A1 (en) | 2022-08-01 | 2024-02-08 | Flagship Pioneering Innovations Vii, Llc | Immunomodulatory Proteins and Associated Methods |
| WO2024035952A1 (en) | 2022-08-12 | 2024-02-15 | Remix Therapeutics Inc. | Methods and compositions for modulating splicing at alternative splice sites |
| WO2024040222A1 (en) | 2022-08-19 | 2024-02-22 | Generation Bio Co. | Cleavable closed-ended dna (cedna) and methods of use thereof |
| EP4327829A1 (en) | 2022-08-26 | 2024-02-28 | Ethris GmbH | Stabilization of lipid or lipidoid nanoparticle suspensions |
| JP2025529925A (ja) | 2022-08-26 | 2025-09-09 | エスリス ゲーエムベーハー | 安定な脂質またはリピドイドナノ粒子懸濁液 |
| AU2023334610A1 (en) | 2022-08-31 | 2025-03-13 | Sail Biomedicines, Inc. | Novel ionizable lipids and lipid nanoparticles and methods of using the same |
| EP4598946A1 (en) | 2022-10-05 | 2025-08-13 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
| WO2024088808A1 (en) | 2022-10-24 | 2024-05-02 | Ags Therapeutics Sas | Extracellular vesicles from microalgae, their biodistribution upon intranasal administration, and uses thereof |
| WO2024097664A1 (en) | 2022-10-31 | 2024-05-10 | Flagship Pioneering Innovations Vi, Llc | Compositions and methods for purifying polyribonucleotides |
| WO2024102762A1 (en) | 2022-11-08 | 2024-05-16 | Orna Therapeutics, Inc. | Lipids and lipid nanoparticle compositions for delivering polynucleotides |
| JP2025537178A (ja) | 2022-11-08 | 2025-11-14 | オーナ セラピューティクス， インコーポレイテッド | 環状ｒｎａ組成物 |
| TW202434728A (zh) | 2022-11-08 | 2024-09-01 | 美商旗艦先鋒創新有限責任公司 | 用於產生環狀多核糖核苷酸的組成物和方法 |
| TW202425959A (zh) | 2022-11-08 | 2024-07-01 | 美商歐納醫療公司 | 遞送多核苷酸的脂質及奈米顆粒組合物 |
| EP4626402A1 (en) | 2022-12-01 | 2025-10-08 | Generation Bio Co. | Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers |
| EP4626444A2 (en) | 2022-12-01 | 2025-10-08 | Generation Bio Co. | Lipid nanoparticles comprising nucleic acids, ionizable lipids, sterols, lipid anchored polymers and helper lipids, their uses |
| IL320873A (en) | 2022-12-01 | 2025-07-01 | Generation Bio Co | Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions containing them |
| CN120615013A (zh) | 2022-12-01 | 2025-09-09 | 世代生物公司 | 用于细胞靶向的隐形脂质纳米颗粒组合物 |
| CN120615126A (zh) | 2022-12-09 | 2025-09-09 | 武田药品工业株式会社 | 经修饰的免疫调节剂 |
| TW202430215A (zh) | 2022-12-14 | 2024-08-01 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | 用於將治療劑遞送至骨之組成物和方法 |
| US20240252520A1 (en) | 2023-01-09 | 2024-08-01 | Beth Israel Deaconess Medical Center, Inc. | Therapeutic agents and their use for treating chronic wounds |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| EP4648794A2 (en) | 2023-01-09 | 2025-11-19 | Flagship Pioneering Innovations VII, LLC | Vaccines and related methods |
| WO2024151673A2 (en) | 2023-01-09 | 2024-07-18 | President And Fellows Of Harvard College | Recombinant nucleic acid molecules and their use in wound healing |
| TW202438515A (zh) | 2023-02-06 | 2024-10-01 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | 免疫調節組合物及相關方法 |
| IL322468A (en) | 2023-02-13 | 2025-09-01 | Flagship Pioneering Innovations Vii Llc | Ionizable lipids containing degradable crosslinkers and lipid carriers for therapeutic compositions |
| IL322201A (en) | 2023-02-17 | 2025-09-01 | Flagship Pioneering Innovations Vii Llc | DNA structures containing modified uracil |
| WO2024173836A2 (en) | 2023-02-17 | 2024-08-22 | Flagship Pioneering Innovations Vii, Llc | Dna compositions comprising modified cytosine |
| KR20250162610A (ko) | 2023-03-15 | 2025-11-18 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | 폴리리보뉴클레오티드를 포함하는 조성물 및 이의 용도 |
| CN121358494A (zh) | 2023-03-15 | 2026-01-16 | 旗舰创业创新第六有限责任公司 | 免疫原性组合物及其用途 |
| WO2024205657A2 (en) | 2023-03-29 | 2024-10-03 | Orna Therapeutics, Inc. | Lipids and lipid nanoparticle compositions for delivering polynucleotides |
| WO2024200823A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof |
| EP4687990A1 (en) | 2023-03-30 | 2026-02-11 | Ose Immunotherapeutics | Method of synthesis of targeted lipid nanoparticle and uses thereof |
| WO2024210160A1 (en) | 2023-04-07 | 2024-10-10 | Takeda Pharmaceutical Company Limited | Conjugation complex |
| WO2024216128A1 (en) | 2023-04-12 | 2024-10-17 | Flagship Pioneering Innovations Vi, Llc | Trems for use in correction of missense mutations |
| EP4695393A1 (en) | 2023-04-12 | 2026-02-18 | Flagship Pioneering Innovations VI, LLC | Modified trems, compositions, and related methods thereof |
| WO2024220746A2 (en) | 2023-04-21 | 2024-10-24 | Flagship Pioneering Innovations Vii, Llc | Rnai agents targeting fatty acid synthase and related methods |
| AU2024269222A1 (en) | 2023-05-05 | 2025-10-09 | Orna Therapeutics, Inc. | Circular rna compositions and methods |
| WO2024236361A1 (en) | 2023-05-15 | 2024-11-21 | Takeda Pharmaceutical Company Limited | Compositions and methods for delivery of nucleic acids to cells |
| WO2024236504A1 (en) | 2023-05-15 | 2024-11-21 | Takeda Pharmaceutical Company Limited | Sequences and methods for delivery of dna and rna |
| WO2024243438A2 (en) | 2023-05-23 | 2024-11-28 | Omega Therapeutics, Inc. | Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression |
| WO2024240962A1 (en) | 2023-05-25 | 2024-11-28 | Ethris Gmbh | Gm-csf-encoding nucleic acids, pharmaceutical compositions, methods and uses thereof |
| CN121311463A (zh) * | 2023-06-07 | 2026-01-09 | 北京因诺惟康医药科技有限公司 | 可电离脂质化合物、包含其的脂质载体及应用 |
| WO2024258829A1 (en) | 2023-06-12 | 2024-12-19 | Flagship Pioneering Innovations Vii, Llc | Sars-cov-2 vaccine compositions and related methods |
| WO2025006684A1 (en) | 2023-06-28 | 2025-01-02 | Flagship Pioneering Innovations Vi, Llc | Circular polyribonucleotides encoding antifusogenic polypeptides |
| AU2024299627A1 (en) | 2023-07-25 | 2026-01-22 | Flagship Pioneering Innovations Vii, Llc | Cas endonucleases and related methods |
| WO2025027116A1 (en) | 2023-08-01 | 2025-02-06 | Institut Curie | Nanoparticles comprising nucleic acid sequences encoding cyclic gmp-amp synthase |
| WO2025042786A1 (en) | 2023-08-18 | 2025-02-27 | Flagship Pioneering Innovations Vi, Llc | Compositions comprising circular polyribonucleotides and uses thereof |
| WO2025045767A1 (en) | 2023-08-25 | 2025-03-06 | Ethris Gmbh | Stabilized lipid and lipidoid nanoparticle formulations with specific surfactant properties for enhanced pharmaceutical applications |
| WO2025049690A1 (en) | 2023-08-29 | 2025-03-06 | Orna Therapeutics, Inc. | Circular polyethylene glycol lipids |
| WO2025054236A2 (en) | 2023-09-06 | 2025-03-13 | Flagship Pioneering Innovations Vii, Llc | Sars-cov-2 vaccine compositions and related methods |
| EP4520345A1 (en) | 2023-09-06 | 2025-03-12 | Myneo Nv | Product |
| WO2025052180A2 (en) | 2023-09-07 | 2025-03-13 | Axelyf ehf. | Lipids and lipid nanoparticles |
| TW202525266A (zh) | 2023-09-18 | 2025-07-01 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | 可電離類脂質組成物及其治療用途 |
| WO2025072331A1 (en) | 2023-09-26 | 2025-04-03 | Flagship Pioneering Innovations Vii, Llc | Cas nucleases and related methods |
| WO2025096807A2 (en) | 2023-10-31 | 2025-05-08 | Flagship Pioneering Innovations Vii, Llc | Novel therapeutic dna forms |
| CN117482066B (zh) * | 2023-11-02 | 2024-08-13 | 深圳市易瑞生物技术股份有限公司 | 脂质组合物和用于脂质组合物的化合物 |
| WO2025101501A1 (en) | 2023-11-07 | 2025-05-15 | Orna Therapeutics, Inc. | Circular rna compositions |
| WO2025106670A1 (en) | 2023-11-14 | 2025-05-22 | Flagship Pioneering Innovations Vii, Llc | Ionizable lipidoid compositions and therapeutic uses thereof |
| WO2025111526A1 (en) | 2023-11-22 | 2025-05-30 | Flagship Pioneering Innovations Vii, Llc | Methods and compositions for treating non-alcoholic fatty liver disease |
| WO2025117877A2 (en) | 2023-12-01 | 2025-06-05 | Flagship Pioneering Innovations Vii, Llc | Cas nucleases and related methods |
| WO2025129128A1 (en) | 2023-12-15 | 2025-06-19 | Vivasor, Inc. | Compositions and methods for non-viral delivery of therapeutic compounds |
| WO2025133951A1 (en) | 2023-12-21 | 2025-06-26 | Genevant Sciences Gmbh | Ionizable lipids suitable for lipid nanoparticles |
| WO2025133115A1 (en) | 2023-12-21 | 2025-06-26 | Ose Immunotherapeutics | Lipid-based nanoparticles comprising il-35 |
| WO2025160334A1 (en) | 2024-01-26 | 2025-07-31 | Flagship Pioneering Innovations Vii, Llc | Immunoreceptor inhibitory proteins and related methods |
| WO2025176847A1 (en) | 2024-02-21 | 2025-08-28 | Ags Therapeutics Sas | Ocular delivery of active agents via microalgae extracellular vesicles |
| WO2025194019A1 (en) | 2024-03-14 | 2025-09-18 | Flagship Pioneering Innovations Vii, Llc | Methods for treating liver fibrosis and non-alcoholic fatty liver disease |
| WO2025210520A1 (en) | 2024-04-04 | 2025-10-09 | Genevant Sciences Gmbh | Lipid nanoparticles for inducing an immunological response |
| WO2025210521A1 (en) | 2024-04-04 | 2025-10-09 | Genevant Sciences Gmbh | Lipid nanoparticles for stimulating t cells |
| WO2025217275A2 (en) | 2024-04-10 | 2025-10-16 | Flagship Pioneering Innovations Vii, Llc | Immune cell targeted compositions and related methods |
| WO2025240680A1 (en) | 2024-05-16 | 2025-11-20 | Flagship Pioneering Innovations Vii, Llc | Immunoreceptor inhibitory proteins and related methods |
| WO2025245188A2 (en) | 2024-05-21 | 2025-11-27 | Flagship Pioneering Innovations Vii, Llc | Methods of treating liver steatosis and non-alcoholic fatty liver disease |
| WO2025245111A1 (en) | 2024-05-22 | 2025-11-27 | Flagship Pioneering Innovations Vii, Llc | Immunoreceptor targeting proteins and related methods |
| US20260000702A1 (en) | 2024-06-26 | 2026-01-01 | Flagship Pioneering Innovations Vii, Llc | Therapeutic circular dna forms |
| WO2026003582A2 (en) | 2024-06-27 | 2026-01-02 | Axelyf ehf. | Lipids and lipid nanoparticles |
| WO2026055543A1 (en) | 2024-09-06 | 2026-03-12 | Flagship Pioneering Innovations Vii, Llc | Modified dna compositions and related methods |
| WO2026055547A1 (en) | 2024-09-06 | 2026-03-12 | Flagship Pioneering Innovations Vii, Llc | Dna compositions and related methods |
Family Cites Families (147)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3817827A (en) | 1972-03-30 | 1974-06-18 | Scott Paper Co | Soft absorbent fibrous webs containing elastomeric bonding material and formed by creping and embossing |
| US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
| US3993754A (en) | 1974-10-09 | 1976-11-23 | The United States Of America As Represented By The United States Energy Research And Development Administration | Liposome-encapsulated actinomycin for cancer chemotherapy |
| US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
| US4086257A (en) | 1976-10-12 | 1978-04-25 | Sears Barry D | Phosphatidyl quaternary ammonium compounds |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| CH624011A5 (enExample) | 1977-08-05 | 1981-07-15 | Battelle Memorial Institute | |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4452901A (en) | 1980-03-20 | 1984-06-05 | Ciba-Geigy Corporation | Electrophoretically transferring electropherograms to nitrocellulose sheets for immuno-assays |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4522803A (en) | 1983-02-04 | 1985-06-11 | The Liposome Company, Inc. | Stable plurilamellar vesicles, their preparation and use |
| US4588578A (en) | 1983-08-08 | 1986-05-13 | The Liposome Company, Inc. | Lipid vesicles prepared in a monophase |
| US5208036A (en) | 1985-01-07 | 1993-05-04 | Syntex (U.S.A.) Inc. | N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| US5453566A (en) | 1986-03-28 | 1995-09-26 | Calgene, Inc. | Antisense regulation of gene expression in plant/cells |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| CA1340323C (en) | 1988-09-20 | 1999-01-19 | Arnold E. Hampel | Rna catalyst for cleaving specific rna sequences |
| GB8822492D0 (en) | 1988-09-24 | 1988-10-26 | Considine J | Apparatus for removing tumours from hollow organs of body |
| US5725871A (en) | 1989-08-18 | 1998-03-10 | Danbiosyst Uk Limited | Drug delivery compositions comprising lysophosphoglycerolipid |
| EP0451221B1 (en) | 1989-08-31 | 1994-10-12 | City Of Hope | Chimeric dna-rna catalytic sequences |
| US5286634A (en) | 1989-09-28 | 1994-02-15 | Stadler Joan K | Synergistic method for host cell transformation |
| US5707644A (en) | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
| US6753423B1 (en) | 1990-01-11 | 2004-06-22 | Isis Pharmaceuticals, Inc. | Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| US6365730B1 (en) | 1990-06-19 | 2002-04-02 | Gene Shears Pty. Limited | DNA-Armed ribozymes and minizymes |
| US5068120A (en) * | 1990-08-01 | 1991-11-26 | Nabisco Brands, Inc. | Amine ester derivatives as low calorie fat mimetics |
| US5789573A (en) | 1990-08-14 | 1998-08-04 | Isis Pharmaceuticals, Inc. | Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2 |
| JP3257675B2 (ja) | 1990-10-12 | 2002-02-18 | マックス−プランク−ゲゼルシャフト ツール フェルデルング デル ビッセンシャフテン エー．ファウ． | 修飾リボザイム |
| DE4216134A1 (de) | 1991-06-20 | 1992-12-24 | Europ Lab Molekularbiolog | Synthetische katalytische oligonukleotidstrukturen |
| US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
| US6831166B2 (en) | 1992-10-23 | 2004-12-14 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
| US5756353A (en) | 1991-12-17 | 1998-05-26 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol-and liposome-based delivery |
| US5652094A (en) | 1992-01-31 | 1997-07-29 | University Of Montreal | Nucleozymes |
| EP0642589A4 (en) | 1992-05-11 | 1997-05-21 | Ribozyme Pharm Inc | METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION. |
| ES2105262T3 (es) | 1992-05-18 | 1997-10-16 | Minnesota Mining & Mfg | Dispositivo de suministro de farmaco a traves de las mucosas. |
| US5792451A (en) | 1994-03-02 | 1998-08-11 | Emisphere Technologies, Inc. | Oral drug delivery compositions and methods |
| WO1994002595A1 (en) | 1992-07-17 | 1994-02-03 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for treatment of animal diseases |
| IL108367A0 (en) | 1993-01-27 | 1994-04-12 | Hektoen Inst For Medical Resea | Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells |
| US5426039A (en) | 1993-09-08 | 1995-06-20 | Bio-Rad Laboratories, Inc. | Direct molecular cloning of primer extended DNA containing an alkane diol |
| US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| US5591317A (en) | 1994-02-16 | 1997-01-07 | Pitts, Jr.; M. Michael | Electrostatic device for water treatment |
| US5631359A (en) | 1994-10-11 | 1997-05-20 | Ribozyme Pharmaceuticals, Inc. | Hairpin ribozymes |
| CA2200952C (en) | 1994-09-30 | 2006-04-11 | Inex Pharmaceuticals Corp. | Novel compositions comprising quaternary ammonium compounds and neutral lipids for the introduction of polyanionic materials into cells |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| US5753613A (en) | 1994-09-30 | 1998-05-19 | Inex Pharmaceuticals Corporation | Compositions for the introduction of polyanionic materials into cells |
| AU3889595A (en) | 1994-10-05 | 1996-05-02 | Amgen, Inc. | Method for inhibiting smooth muscle cell proliferation and oligonucleotides for use therein |
| US5783683A (en) | 1995-01-10 | 1998-07-21 | Genta Inc. | Antisense oligonucleotides which reduce expression of the FGFRI gene |
| US5580579A (en) | 1995-02-15 | 1996-12-03 | Nano Systems L.L.C. | Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers |
| IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| US5646241A (en) * | 1995-05-12 | 1997-07-08 | Quantum Materials, Inc. | Bleed resistant cyanate ester-containing compositions |
| ATE285477T1 (de) | 1995-06-07 | 2005-01-15 | Inex Pharmaceutical Corp | Herstellung von lipid-nukleinsäure partikeln duch ein hydrophobische lipid-nukleinsäuree komplexe zwischenprodukt und zur verwendung in der gentransfer |
| US5705385A (en) | 1995-06-07 | 1998-01-06 | Inex Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US5747470A (en) | 1995-06-07 | 1998-05-05 | Gen-Probe Incorporated | Method for inhibiting cellular proliferation using antisense oligonucleotides to gp130 mRNA |
| US7422902B1 (en) | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US5981501A (en) | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
| US20030216335A1 (en) | 2001-11-30 | 2003-11-20 | Jennifer Lockridge | Method and reagent for the modulation of female reproductive diseases and conditions |
| US20040142895A1 (en) | 1995-10-26 | 2004-07-22 | Sirna Therapeutics, Inc. | Nucleic acid-based modulation of gene expression in the vascular endothelial growth factor pathway |
| US5998203A (en) | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
| US6713069B1 (en) | 1996-04-16 | 2004-03-30 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Compositions and methods for detecting, preventing, and treating African Hemorrhagic Fever |
| US20050119470A1 (en) | 1996-06-06 | 2005-06-02 | Muthiah Manoharan | Conjugated oligomeric compounds and their use in gene modulation |
| US6111085A (en) | 1996-09-13 | 2000-08-29 | Isis Pharmaceuticals, Inc. | Carbamate-derivatized nucleosides and oligonucleosides |
| US5739119A (en) | 1996-11-15 | 1998-04-14 | Galli; Rachel L. | Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| WO1998051278A2 (en) | 1997-05-14 | 1998-11-19 | Inex Pharmaceuticals Corporation | High efficiency encapsulation of charged therapeutic agents in lipid vesicles |
| WO1999005303A1 (en) | 1997-07-24 | 1999-02-04 | Inex Pharmaceuticals Corporation | Preparation of lipid-nucleic acid particles using a solvent extraction and direct hydration method |
| US6320017B1 (en) | 1997-12-23 | 2001-11-20 | Inex Pharmaceuticals Corp. | Polyamide oligomers |
| WO2000003683A2 (en) | 1998-07-20 | 2000-01-27 | Inex Pharmaceuticals Corporation | Liposomal encapsulated nucleic acid-complexes |
| JP5117648B2 (ja) | 1999-04-20 | 2013-01-16 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | カチオン性ｐｅｇ脂質および使用方法。 |
| US6852334B1 (en) | 1999-04-20 | 2005-02-08 | The University Of British Columbia | Cationic peg-lipids and methods of use |
| IL148359A0 (en) | 1999-08-27 | 2002-09-12 | Inex Pharmaceuticals Corp | Pharmaceutical compositions containing an oligodeoxynucleotide |
| US7833992B2 (en) | 2001-05-18 | 2010-11-16 | Merck Sharpe & Dohme | Conjugates and compositions for cellular delivery |
| US7491805B2 (en) | 2001-05-18 | 2009-02-17 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| US8202979B2 (en) | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
| US7189705B2 (en) | 2000-04-20 | 2007-03-13 | The University Of British Columbia | Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers |
| AU2001297693A1 (en) | 2000-12-08 | 2002-09-12 | Coley Pharmaceutical Gmbh | Cpg-like nucleic acids and methods of use thereof |
| US7053150B2 (en) | 2000-12-18 | 2006-05-30 | Nektar Therapeutics Al, Corporation | Segmented polymers and their conjugates |
| TW593427B (en) | 2000-12-18 | 2004-06-21 | Nektar Therapeutics Al Corp | Synthesis of high molecular weight non-peptidic polymer derivatives |
| US20030077829A1 (en) | 2001-04-30 | 2003-04-24 | Protiva Biotherapeutics Inc.. | Lipid-based formulations |
| US7109165B2 (en) | 2001-05-18 | 2006-09-19 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| US20070173473A1 (en) | 2001-05-18 | 2007-07-26 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of proprotein convertase subtilisin Kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA) |
| US20050282188A1 (en) | 2001-05-18 | 2005-12-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
| US20030130186A1 (en) | 2001-07-20 | 2003-07-10 | Chandra Vargeese | Conjugates and compositions for cellular delivery |
| US7514099B2 (en) | 2005-02-14 | 2009-04-07 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
| GB0118517D0 (en) * | 2001-07-30 | 2001-09-19 | Mitsubishi Tokyo Pharm Inc | Compound |
| DE10163098B4 (de) | 2001-10-12 | 2005-06-02 | Alnylam Europe Ag | Verfahren zur Hemmung der Replikation von Viren |
| AU2003207708A1 (en) | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of map kinase genes |
| EP1476552A2 (en) | 2002-02-22 | 2004-11-17 | Strebhardt, Klaus, Prof. Dr. | Agent for inhibiting development or progress of proliferative diseases and especially cancer diseases and pharmaceutical composition containing said agent |
| DE60334618D1 (de) | 2002-06-28 | 2010-12-02 | Protiva Biotherapeutics Inc | Verfahren und vorrichtung zur herstellung von liposomen |
| AU2003261231A1 (en) | 2002-07-26 | 2004-02-16 | Chiron Corporation | Modified small interfering rna molecules and methods of use |
| US8090542B2 (en) | 2002-11-14 | 2012-01-03 | Dharmacon Inc. | Functional and hyperfunctional siRNA |
| WO2006006948A2 (en) | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
| US20040167090A1 (en) | 2003-02-21 | 2004-08-26 | Monahan Sean D. | Covalent modification of RNA for in vitro and in vivo delivery |
| US20040185559A1 (en) | 2003-03-21 | 2004-09-23 | Isis Pharmaceuticals Inc. | Modulation of diacylglycerol acyltransferase 1 expression |
| EP1608735A4 (en) | 2003-04-03 | 2008-11-05 | Alnylam Pharmaceuticals | RNAI CONJUGATES |
| CA2521464C (en) | 2003-04-09 | 2013-02-05 | Alnylam Pharmaceuticals, Inc. | Irna conjugates |
| EP2669377A3 (en) | 2003-04-17 | 2015-10-14 | Alnylam Pharmaceuticals Inc. | Modified iRNA agents |
| CN101291653B (zh) | 2003-07-16 | 2012-06-27 | 普洛体维生物治疗公司 | 脂质包封的干扰rna |
| US7825235B2 (en) | 2003-08-18 | 2010-11-02 | Isis Pharmaceuticals, Inc. | Modulation of diacylglycerol acyltransferase 2 expression |
| KR101164256B1 (ko) | 2003-09-15 | 2012-07-10 | 프로티바 바이오쎄라퓨틱스, 인코포레이티드 | 폴리에틸렌글리콜 개질된 지질 화합물 및 그의 용도 |
| US20070265220A1 (en) | 2004-03-15 | 2007-11-15 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
| US8084599B2 (en) | 2004-03-15 | 2011-12-27 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
| EP1766035B1 (en) | 2004-06-07 | 2011-12-07 | Protiva Biotherapeutics Inc. | Lipid encapsulated interfering rna |
| EP1781593B1 (en) | 2004-06-07 | 2011-12-14 | Protiva Biotherapeutics Inc. | Cationic lipids and methods of use |
| WO2006031901A2 (en) | 2004-09-10 | 2006-03-23 | Somagenics, Inc. | SMALL INTERFERING RNAs THAT EFFICIENTLY INHIBIT VIRAL GENE EXPRESSION AND METHODS OF USE THEREOF |
| CN101133074B (zh) | 2004-09-24 | 2012-05-30 | 阿尔尼拉姆医药品有限公司 | APOB的RNAi调节及其用途 |
| US20060134189A1 (en) | 2004-11-17 | 2006-06-22 | Protiva Biotherapeutics, Inc | siRNA silencing of apolipoprotein B |
| US7404969B2 (en) | 2005-02-14 | 2008-07-29 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
| WO2007012191A1 (en) | 2005-07-27 | 2007-02-01 | Protiva Biotherapeutics, Inc. | Systems and methods for manufacturing liposomes |
| US7838658B2 (en) | 2005-10-20 | 2010-11-23 | Ian Maclachlan | siRNA silencing of filovirus gene expression |
| CN101346393B (zh) | 2005-11-02 | 2015-07-22 | 普洛体维生物治疗公司 | 修饰的siRNA分子及其应用 |
| WO2007056861A1 (en) | 2005-11-18 | 2007-05-24 | Protiva Biotherapeutics, Inc. | Sirna silencing of influenza virus gene expression |
| GB0605900D0 (en) * | 2006-03-23 | 2006-05-03 | Lipigen As | Modulators of nuclear receptors |
| EP2194128B1 (en) | 2006-05-11 | 2012-08-01 | Alnylam Pharmaceuticals Inc. | Compositions and methods for inhibiting expression of the PCSK9 gene |
| US8598333B2 (en) | 2006-05-26 | 2013-12-03 | Alnylam Pharmaceuticals, Inc. | SiRNA silencing of genes expressed in cancer |
| EP2695608B1 (en) | 2006-10-03 | 2016-11-23 | Arbutus Biopharma Corporation | Lipid containing formulations |
| KR100996975B1 (ko) * | 2007-08-24 | 2010-11-29 | 한국화학연구원 | 혈류 내 순환시간 증가를 위한 단백질로 수식된 리포솜 및이의 제조방법 |
| EP2238251B1 (en) | 2007-12-27 | 2015-02-11 | Protiva Biotherapeutics Inc. | Silencing of polo-like kinase expression using interfering rna |
| CA2711236A1 (en) * | 2008-01-02 | 2009-07-16 | Alnylam Pharmaceuticals, Inc. | Screening method for selected amino lipid-containing compositions |
| EP2224912B1 (en) * | 2008-01-02 | 2016-05-11 | TEKMIRA Pharmaceuticals Corporation | Improved compositions and methods for the delivery of nucleic acids |
| AU2009236219B8 (en) | 2008-04-15 | 2015-06-25 | Arbutus Biopharma Corporation | Silencing of CSN5 gene expression using interfering RNA |
| CA2721333C (en) | 2008-04-15 | 2020-12-01 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for nucleic acid delivery |
| JP5642673B2 (ja) | 2008-07-10 | 2014-12-17 | セリナ・セラピユーテイツクス・インコーポレーテツド | 不活性末端基を有するポリオキサゾリン類、保護された開始基から調製されるポリオキサゾリン類及び関連化合物 |
| KR100996976B1 (ko) | 2008-08-27 | 2010-11-29 | 현대엔지니어링 주식회사 | 장수명 ｍｔｏ 반응용 촉매 및 이의 제조방법 |
| JP5777519B2 (ja) | 2008-10-09 | 2015-09-09 | テクミラ ファーマシューティカルズ コーポレイション | 改良されたアミノ脂質および核酸の送達方法 |
| DK2355851T3 (en) * | 2008-11-10 | 2018-06-25 | Arbutus Biopharma Corp | Newly known lipids and compositions for release of therapeutic agents |
| CA2764609C (en) * | 2009-06-10 | 2018-10-02 | Alnylam Pharmaceuticals, Inc. | Improved cationic lipid of formula i |
| WO2011000106A1 (en) * | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Improved cationic lipids and methods for the delivery of therapeutic agents |
| JP5766188B2 (ja) | 2009-07-01 | 2015-08-19 | プロチバ バイオセラピューティクス インコーポレイティッド | 固形腫瘍に治療剤を送達するための脂質製剤 |
| AU2010330814B2 (en) * | 2009-12-18 | 2017-01-12 | Acuitas Therapeutics Inc. | Methods and compositions for delivery of nucleic acids |
| US9254327B2 (en) * | 2010-05-10 | 2016-02-09 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for delivery of active agents |
| EP2569276B1 (en) | 2010-05-12 | 2021-02-24 | Arbutus Biopharma Corporation | Novel cationic lipids and methods of use thereof |
| WO2011141704A1 (en) * | 2010-05-12 | 2011-11-17 | Protiva Biotherapeutics, Inc | Novel cyclic cationic lipids and methods of use |
| US8865675B2 (en) * | 2010-05-12 | 2014-10-21 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing apolipoprotein B |
| DK2575767T3 (en) * | 2010-06-04 | 2017-03-13 | Sirna Therapeutics Inc | HOWEVER UNKNOWN LOW MOLECULAR CATIONIC LIPIDS TO PROCESS OIGONUCLEOTIDES |
| US8466122B2 (en) * | 2010-09-17 | 2013-06-18 | Protiva Biotherapeutics, Inc. | Trialkyl cationic lipids and methods of use thereof |
| EP3485913A1 (en) | 2010-10-21 | 2019-05-22 | Sirna Therapeutics, Inc. | Low molecular weight cationic lipids for oligonucleotide delivery |
| NZ700075A (en) | 2012-02-24 | 2016-05-27 | Protiva Biotherapeutics Inc | Trialkyl cationic lipids and methods of use thereof |
| US9744103B1 (en) | 2013-03-08 | 2017-08-29 | Chad Ricker | Infant teething apparatus |
| WO2015011633A1 (en) | 2013-07-23 | 2015-01-29 | Protiva Biotherapeutics, Inc. | Compositions and methods for delivering messenger rna |
| WO2017015504A1 (en) | 2015-07-21 | 2017-01-26 | Scheibel Steven Frederick | Treatment and prevention of anal conditions |
-
2013
- 2013-02-22 NZ NZ700075A patent/NZ700075A/en unknown
- 2013-02-22 CA CA2865412A patent/CA2865412C/en active Active
- 2013-02-22 RU RU2014138476A patent/RU2718053C2/ru active
- 2013-02-22 KR KR1020147026598A patent/KR102075810B1/ko active Active
- 2013-02-22 US US14/380,536 patent/US9352042B2/en active Active
- 2013-02-22 DK DK13709634.3T patent/DK2817287T3/da active
- 2013-02-22 ES ES13709634T patent/ES2702874T3/es active Active
- 2013-02-22 KR KR1020217010379A patent/KR102384791B1/ko active Active
- 2013-02-22 MX MX2018006897A patent/MX392812B/es unknown
- 2013-02-22 KR KR1020227011265A patent/KR20220045089A/ko not_active Ceased
- 2013-02-22 LT LTEP13709634.3T patent/LT2817287T/lt unknown
- 2013-02-22 RU RU2020111326A patent/RU2020111326A/ru unknown
- 2013-02-22 EP EP13709634.3A patent/EP2817287B1/en active Active
- 2013-02-22 RS RS20181562A patent/RS58077B1/sr unknown
- 2013-02-22 WO PCT/US2013/027469 patent/WO2013126803A1/en not_active Ceased
- 2013-02-22 HR HRP20182156TT patent/HRP20182156T1/hr unknown
- 2013-02-22 EP EP18193953.9A patent/EP3473611B1/en active Active
- 2013-02-22 HU HUE13709634A patent/HUE041494T2/hu unknown
- 2013-02-22 BR BR112014020824-7A patent/BR112014020824B1/pt active IP Right Grant
- 2013-02-22 ES ES18193953T patent/ES2898912T3/es active Active
- 2013-02-22 EP EP21202091.1A patent/EP3988104A1/en not_active Withdrawn
- 2013-02-22 MX MX2014010211A patent/MX356904B/es active IP Right Grant
- 2013-02-22 UA UAA201410393A patent/UA120026C2/uk unknown
- 2013-02-22 CN CN201910048388.5A patent/CN110003030A/zh active Pending
- 2013-02-22 SG SG11201405157PA patent/SG11201405157PA/en unknown
- 2013-02-22 CN CN201380020104.2A patent/CN104321304A/zh active Pending
- 2013-02-22 KR KR1020207003227A patent/KR102239887B1/ko active Active
- 2013-02-22 PT PT13709634T patent/PT2817287T/pt unknown
- 2013-02-22 PL PL13709634T patent/PL2817287T3/pl unknown
- 2013-02-22 AU AU2013222179A patent/AU2013222179B2/en active Active
- 2013-02-22 SI SI201331293T patent/SI2817287T1/sl unknown
- 2013-02-22 JP JP2014558898A patent/JP6275655B2/ja active Active
-
2014
- 2014-08-22 PH PH12014501901A patent/PH12014501901B1/en unknown
- 2014-08-22 MX MX2022006512A patent/MX2022006512A/es unknown
- 2014-08-24 IL IL234266A patent/IL234266B/en active IP Right Grant
- 2014-09-19 ZA ZA2014/06896A patent/ZA201406896B/en unknown
-
2016
- 2016-05-09 US US15/150,016 patent/US10561732B2/en active Active
-
2017
- 2017-12-11 JP JP2017236756A patent/JP6789918B2/ja active Active
-
2019
- 2019-01-03 CY CY20191100004T patent/CY1121232T1/el unknown
-
2020
- 2020-01-30 US US16/776,950 patent/US11395854B2/en active Active
- 2020-08-25 IL IL276924A patent/IL276924A/en unknown
- 2020-11-04 JP JP2020184356A patent/JP7110297B2/ja active Active
-
2022
- 2022-02-27 IL IL290931A patent/IL290931A/en unknown
- 2022-06-17 US US17/843,188 patent/US20230109183A1/en not_active Abandoned
- 2022-07-20 JP JP2022115626A patent/JP2022140533A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015509505A5 (enExample) | ||
| RU2020111326A (ru) | Триалкил катионные липиды и способы их использования | |
| CA2532228C (en) | Lipid encapsulated interfering rna | |
| JP2021073263A (ja) | Ｒｎａ送達のためのイオン化可能なカチオン性脂質 | |
| CA2569664C (en) | Lipid encapsulated interfering rna | |
| JP2019508371A5 (enExample) | ||
| JP2020514366A5 (enExample) | ||
| JP7325327B2 (ja) | インフュージョンリアクションを改善するための方法 | |
| JP2011507534A5 (enExample) | ||
| JP6389477B2 (ja) | カチオン性脂質 | |
| JP2011516586A5 (enExample) | ||
| JP2025505971A (ja) | 脂質ナノ粒子用のイオン化できるカチオン性脂質 | |
| WO2018222910A1 (en) | Therapeutic compositions and methods for treating hepatitis b | |
| JP2024105468A (ja) | Ｂ型肝炎を治療するための治療用組成物及び方法 | |
| TW201919653A (zh) | 用於治療ｂ型肝炎之治療組合物及方法 | |
| JPWO2023144798A5 (enExample) | ||
| US20070054873A1 (en) | Glucocorticoid modulation of nucleic acid-mediated immune stimulation | |
| US20240417738A1 (en) | Immunotherapies for the treatment of cancer | |
| WO2018225873A1 (ja) | 核酸含有ナノ粒子 | |
| EP4698581A1 (en) | Conjugated polyethyleneimine compounds and compositions, and uses thereof for the treatment of atherosclerosis, cardiovascular, and lung disease | |
| WO2024209011A1 (en) | Nanoparticle compositions comprising one or more variants of poly(d,l-lactic- co-glycolic acid) |